Bladder Cancer Treatment by Stage

Bladder cancer treatment turns on a single question. Has the tumor grown into the muscle wall of the bladder?

Ta, Tis, and T1 tumors have not. They sit in the lining or just under it. These are treated through the urethra, with drugs delivered straight into the bladder.

T2 and above have reached muscle. Treatment becomes major surgery or radiation, plus chemotherapy through the bloodstream.

Everything below follows that split.

These stages are rarely fatal on their own. NCI says patients with stage I tumors are unlikely to die of bladder cancer. The problem is different. The bladder keeps making new tumors.

The number is stark. One series followed Ta and T1 patients for at least 20 years, or until death. The risk of recurrence after the first resection was 80%.

Recurrence is not the main worry, though. Progression is. One series followed 125 patients with TaG3 tumors, which are high grade. Over 15 to 20 years, 39% progressed to more advanced disease. Another 26% died of urothelial cancer. Among 23 patients with low-grade TaG1 tumors, none died and 5% progressed.

NCI lists five risk factors for recurrence and progression:

• High-grade disease.
• Carcinoma in situ present.
• Tumor larger than 3 cm.
• Multiple tumors.
• A history of prior bladder cancer.

Transurethral resection with fulguration is the most common and most conservative approach. A scope goes in through the urethra. The tumor is cut away, and the base is burned. NCI lists resection on its own as one acceptable option at this stage, so not everyone gets the same additions afterwards.

Most tumors come back. So one dose of chemotherapy is often put into the bladder soon after the procedure. Not always, though. It is aimed at lower-risk tumors, and it is withheld when the bladder wall may have been perforated or the resection was extensive, because the drug can then leak into surrounding tissue and cause serious harm. The surgeon makes that call in theatre. A meta-analysis pooled seven randomized trials and 1,476 patients with Ta or T1 disease. The single dose cut the odds of recurrence by 39%, an odds ratio of 0.61. Relapse ran 48% with resection alone and 37% with the added dose.

That single dose is not enough for everyone. With multiple tumors, most patients still relapse. NCI says the treatment is not sufficient by itself in that group. For them NCI lists two further routes: repeated doses of BCG, a live bacterial preparation, or more chemotherapy into the bladder. Which one is offered follows the risk of return and of progression, not a single fixed order.

Segmental cystectomy is rarely used. Radical cystectomy is kept for rare, carefully selected cases. Those involve extensive or drug-resistant high-grade surface tumors.

Staging depends on what the pathologist can see. To say whether cancer reached muscle, the sample must hold muscularis propria. That is the muscle layer itself.

NCI calls a repeat resection generally mandatory in one case. That is a T1 or high-grade noninvasive tumor with no muscularis propria in the first sample. Many experts repeat it routinely, within 2 to 6 weeks.

The reason is a finding that keeps repeating. One series did a second resection on 38 patients with Tis or Ta disease. It found lamina propria invasion in 9 patients, or 24%. It found muscle invasion in 3 patients, or 8%. Those results change the plan entirely.

Here NCI is unusually direct about what is and is not known.

The two most common treatments are radical cystectomy and radiation therapy. No strong randomized evidence says which is better. Strong evidence does say both work better with chemotherapy added. Two approaches carry the highest levels of evidence. One is radical cystectomy after multi-drug cisplatin-based chemotherapy. The other is radiation therapy given with chemotherapy at the same time.

This is a major operation, and the details matter for anyone weighing it.

It removes the bladder and nearby tissue, plus a pelvic lymph node dissection. In men it also removes the prostate and seminal vesicles. In women it also removes the uterus, fallopian tubes, ovaries, the front wall of the vagina, and the urethra.

Death around the time of surgery runs 2% to 3% at centers of excellence. Ileus, a short-term shutdown of the bowel, is a common problem. Most men have erectile dysfunction afterward. Sexual problems are common in women too. One study followed 27 women after the operation. Of those, 45% had less ability to reach orgasm, 41% had less lubrication, 37% had less desire, and 22% had pain with intercourse.

Even at expert centers, recurrence after cystectomy for muscle-invasive disease runs about 30% to 40%. Five-year overall survival is 50% to 60%, and it varies by stage. Adding radiation before cystectomy did not improve survival in a randomized trial.

Two approaches have randomized evidence.

Cisplatin-based combination chemotherapy before cystectomy is the better-supported order. Giving it first may shrink the tumor. It also treats hidden spread earlier, and it is often easier to tolerate than chemotherapy after surgery.

The NIAGARA trial added immunotherapy to that plan. It enrolled 1,063 patients with clinical stage T2 or higher disease. All had a creatinine clearance of at least 40 mL/min. One arm got durvalumab by infusion alongside gemcitabine and cisplatin before surgery, then further durvalumab afterwards. At 24 months, overall survival was 82.2% with durvalumab and 75.2% without. Event-free survival was 67.8% versus 59.8%. Serious treatment-related side effects were nearly equal, at 40.6% and 40.9%. Those results were reported in 2024. NIAGARA supports this as an option for people fit for cisplatin who meet the trial's eligibility; whether it fits you, and on what schedule, is a decision for your oncology and surgical team together.

For anyone weighing chemotherapy timing, our page on newly diagnosed bladder cancer covers the earlier steps.

NCI is plain here as well. Few patients with stage IV disease can be cured. For many, the aim is relieving symptoms. Cure stays possible mainly in one case: disease that has spread only to nearby pelvic organs or regional lymph nodes.

NCI names enfortumab vedotin plus pembrolizumab a first-line option for people with no contraindication to it, and lists chemotherapy with immunotherapy, chemotherapy alone, systemic therapy before cystectomy, radiation, and palliative surgery alongside it. The EV-302 trial is what moved that combination to the front of the list. It randomized 886 patients to one of two arms. One got enfortumab vedotin plus pembrolizumab. The other got gemcitabine with cisplatin or carboplatin. Median overall survival was 31.5 months versus 16.1 months, a hazard ratio of 0.47. Progression-free survival was 12.5 months versus 6.3 months. Serious side effects were lower in the combination arm, at 55.9% versus 69.5%. The pattern differed, though. The common serious events were skin reactions, nerve damage in the hands and feet, high blood sugar, and low neutrophils.

Enfortumab vedotin is an antibody-drug conjugate. Its antibody locks onto nectin-4 on bladder cancer cells. It carries monomethyl auristatin E, a microtubule inhibitor, inside the cell. Our page on antibody-drug conjugates explains how that class works.

An alternative is chemotherapy plus immunotherapy. In CheckMate901, 608 patients got gemcitabine and cisplatin, with or without nivolumab. Median overall survival was 21.7 months versus 18.9 months.

FGFR is the one to ask about. Roughly 20% of metastatic urothelial carcinomas of the bladder carry an FGFR variant. In tumors of the ureters or renal pelvis, the figure is 35%.

Erdafitinib blocks FGFR 1 through 4. The THOR trial enrolled 266 patients with FGFR2 or FGFR3 variants or fusions. All had already received PD-1 or PD-L1 therapy. They were randomized to erdafitinib or chemotherapy. Median overall survival was 12.1 months versus 7.8 months. Median progression-free survival was 5.6 months versus 2.7 months. The side effects are distinctive. In an earlier trial, low blood phosphate hit 77% of patients, along with mouth sores, diarrhea, and dry mouth.

This is worth knowing, because older pages still list them.

Atezolizumab was voluntarily withdrawn in 2022 as a first-line option here. The setting was locally advanced or metastatic urothelial cancer. The IMvigor130 trial had shown no significant overall survival difference in two analyses.

Durvalumab was voluntarily withdrawn in 2021 as a first-line therapy in the same setting. The DANUBE trial had shown no significant survival gain. Durvalumab still has a role given around surgery, as the NIAGARA results above show. The two situations are not the same, and the difference is easy to lose.

• Call 911 or go to an emergency department if you cannot pass urine at all, or if bleeding with clots comes with severe pain in the abdomen, side or back.
• Telephone your cancer team immediately, night or day, if your temperature reaches 100.4°F (38°C) or higher during chemotherapy, or you get chills with it. Cisplatin-based regimens drop the white cells, and CDC counts a fever in that window as a medical emergency rather than a same-day call (CDC). Do not take a fever reducer first, and do not wait for a callback. If the team cannot be reached fast, go to an emergency department and say on arrival that you are having chemotherapy.
• Call your care team the same day if you have a cough, or redness around a line, without a fever.
• Call your care team the same day if you are on enfortumab vedotin and a rash starts to blister or peel, or sores appear in the mouth, eyes or genitals. Severe skin reactions are the drug's boxed warning, and they cluster in the first cycle.
• Call 911 or go to an emergency department if chest pain starts, or breathlessness comes on at rest, while you are on enfortumab vedotin.
• Call your care team within a day or two if a cough is new or worsening on enfortumab vedotin, or breathlessness has crept up only on exertion. Lung inflammation is a known effect of the drug.
• Call your care team within a day or two if thirst and passing urine increase sharply, or if numbness, tingling or weakness starts in the hands and feet. High blood sugar and nerve damage were the common serious effects in EV-302, and both are picked up early if reported.

• National Cancer Institute, Bladder Cancer Treatment (PDQ) - Health Professional Version, updated May 2, 2025, accessed August 6, 2026
• National Cancer Institute, Bladder Cancer Treatment by Stage, accessed August 6, 2026
• DailyMed, PADCEV (enfortumab vedotin-ejfv) prescribing information, accessed August 11, 2026
• National Cancer Institute, Infection and Neutropenia During Cancer Treatment, accessed August 11, 2026
• Centers for Disease Control and Prevention, Watch Out for Fever, accessed August 13, 2026
• MedlinePlus, Urine - bloody, accessed August 11, 2026